3 terminated, 3 withdrawn, 2 completed, 1 unknown. 5 Phase 1, 4 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 3, Unknown 1, Withdrawn 1 |
| Phase 2 | 4 | Withdrawn 2, Completed 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow 4D pharma plc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's MRx0029, MRx0005 - Idiopathic Parkinson Disease | Phase 1 | Withdrawn | 4D pharma plc | 2022-05-01 | 2023-04-27 | |
| Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma MRx0518, Avelumab 20 mg/mL Intravenous Solution (IV) - Urothelial Carcinoma | Phase 2 | Withdrawn | 4D pharma plc | 2022-03-01 | 2023-04-18 | |
| A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19 MRx-4DP0004, Placebo - COVID-19 | Phase 2 | Withdrawn | 4D pharma plc | 2020-08-01 | 2021-06-16 | |
| A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer MRx0518, Hypofractionated Preoperative Radiation - Pancreatic Cancer | Phase 1 | Terminated | 4D pharma plc | 13 | 2019-12-20 | 2023-06-02 |
| A Study of MRx-4DP0004 in Asthma MRx-4DP0004, Placebo - Asthma | Phase 1 | Terminated | 4D pharma plc | 34 | 2019-07-04 | 2024-04-17 |
| MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour MRx0518 Capsules, MRx0518/placebo Capsules - Melanoma, Breast Cancer | Phase 1 | Unknown | Imperial College London | 120 | 2019-04-10 | 2022-08-11 |
| Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA] - Oncology, Solid Tumor | Phase 1 / Phase 2 | Terminated | 4D pharma plc | 63 | 2019-01-10 | 2023-06-01 |
| A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome Blautix, Placebo - Irritable Bowel Syndrome | Phase 2 | Completed | 4D pharma plc | 366 | 2018-10-11 | 2022-01-11 |
| Study of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease Thetanix, Placebo - Crohn's Disease | Not applicable | Completed | 4D pharma plc | 18 | 2015-12-01 | 2018-06-28 |
Melanoma (2) · Neoplasms (2) · Urinary Bladder Neoplasms (2) · Asthma (1) · Breast Neoplasms (1) · COVID-19 (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Constipation (1) · Coronavirus Infections (1) · Crohn Disease (1) · Diarrhea (1) · Head and Neck Neoplasms (1) · Irritable Bowel Syndrome (1)
avelumab (1) · pembrolizumab (1)
United Kingdom (5) · United States (5) · Ireland (1)
Amishi Y Shah, MD (1) · Christopher Brightling, Professor (1) · Cullen M Taniguchi, MD (1) · David Wilson, MD DCH FRCP(Edin) FRCPCH (1) · Dinesh Saralaya, MBBS, MD, MRCP, FRCP (1) · Dr Jonathan Krell (1) · Eamonn Quigley (1) · Richard Hansen, MB ChB PhD FRCPCH (1) · Shubham Pant, MD (1)